Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, which indicates that treatment effects might have been exaggerated, concludes a new study.
from Latest Science News -- ScienceDaily https://ift.tt/31A1EwW
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment